Literature DB >> 6200955

The role of hepatic biotransformation in mediating the acute toxicity of the phosphorothionate insecticide chlorpyrifos.

L G Sultatos, M Shao, S D Murphy.   

Abstract

The apparent (app) Km and app Vmax for mouse hepatic microsomal oxidative detoxification of chlorpyrifos to 3,5,6-tricholoro-2-pyridinol were 16.10 +/- 6.8 microM and 263.2 +/- 22.5 nmol/liver/min, respectively. The app Km and app Vmax for the oxidative activation of chlorpyrifos to chlorpyrifos oxon were 20.0 +/- 6.5 microM and 126.1 +/- 14.6 nmol/liver/min, respectively, whereas the app Km and app Vmax for hepatic microsomal hydrolysis of chlorpyrifos oxon to 3,5,6-trichloro-2-pyridinol were 1.87 +/- 0.36 mM and 89,450.7 +/- 12,087.3 nmol/liver/min, respectively. Under first-order conditions the capacity of mouse hepatic microsomes to detoxify chlorpyrifos oxon exceeded their capacity to generate this potent cholinesterase inhibitor from chlorpyrifos by a factor of 7.6. Pretreatment of mice with phenobarbital (70 mg/kg daily for 4 days) resulted in a 2.5-fold increase in the app Vmax's for oxidative activation and detoxification of chlorpyrifos, and a 1.6-fold increase in the app Vmax for hydrolysis of chlorpyrifos oxon. The app Km's were not altered by phenobarbital pretreatment. Administration of beta-naphthoflavone (80 mg/kg/daily for 2 days) to mice resulted in a slight decrease in the app Vmax's for oxidative activation and detoxification of chlorpyrifos, without altering the app Km's of the same reactions, or the hydrolysis of chlorpyrifos oxon. Phenobarbital and beta-naphthoflavone increased and decreased, respectively, the predicted hepatic clearance of chlorpyrifos. The acute toxicity of chlorpyrifos was slightly antagonized by phenobarbital pretreatment, but was potentiated by beta-naphthoflavone administration. These pretreatments did not affect cholinesterase, nonspecific esterase, or plasma A-esterase activities. Collectively, these results suggest that chlorpyrifos oxon formed within the liver does not escape hydrolysis by the liver, and that extrahepatic sites of activation are important in directly mediating the acute toxicity of chlorpyrifos.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200955     DOI: 10.1016/0041-008x(84)90053-x

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

1.  Determination of chlorpyrifos and its major breakdown products in technical formulations.

Authors:  W J Allender; J Keegan
Journal:  Bull Environ Contam Toxicol       Date:  1991-02       Impact factor: 2.151

2.  Lentiviral-mediated RNAi knockdown yields a novel mouse model for studying Cyp2b function.

Authors:  Basma Damiri; Eric Holle; Xianzhong Yu; William S Baldwin
Journal:  Toxicol Sci       Date:  2011-11-14       Impact factor: 4.849

3.  Oral and dermal absorption of chlorpyrifos: a human volunteer study.

Authors:  P Griffin; H Mason; K Heywood; J Cocker
Journal:  Occup Environ Med       Date:  1999-01       Impact factor: 4.402

4.  Chlorpyrifos-induced delayed polyneuropathy.

Authors:  E Capodicasa; M L Scapellato; A Moretto; S Caroldi; M Lotti
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

5.  Effects of chlorpyrifos on non-cholinergic toxicity endpoints in immortalized and primary rat hepatocytes under normal and hepatosteatotic conditions.

Authors:  SandeepReddy Kondakala; Lucie Henein; Erin McDevitt; Matthew K Ross; George Eli Howell
Journal:  Toxicol In Vitro       Date:  2022-02-11       Impact factor: 3.500

6.  The carbamate insecticide ZZ-Aphox induced structural changes of gills, liver, gall-bladder, heart, and notochord of Rana perezi tadpoles.

Authors:  M Pilar Honrubia; M Paz Herráez; R Alvarez
Journal:  Arch Environ Contam Toxicol       Date:  1993-08       Impact factor: 2.804

Review 7.  Pharmacokinetics and molecular detoxication.

Authors:  J R Cashman; B Y Perotti; C E Berkman; J Lin
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.